Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44

References

Page 1

	Year	Citations
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma F. Stephen Hodi, Steven O’Day, David F. McDermott, New England Journal of Medicine	2010	14.9K
Mapping and quantifying mammalian transcriptomes by RNA-Seq A Mortazavi, Brian A. Williams, Kenneth McCue, Nature Methods Functional GenomicsGeneticsTranscriptomics TechnologyMammalian TranscriptomesLong Non-coding Rna	2008	14K
A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff Pablo Cingolani, Adrian E. Platts, Le Lily Wang, Fly GeneticsGenetic EpidemiologyHuman PolymorphismGenomicsSnp Frequency	2012	12.1K
A framework for variation discovery and genotyping using next-generation DNA sequencing data Mark A. DePristo, Eric Banks, Ryan Poplin, Nature Genetics Dna SequencingSequencingMedicineGeneticsComputational Genomics	2011	12.1K
Signatures of mutational processes in human cancer Nature Somatic VariantTumor HeterogeneityMutational ProcessesCancer GeneticsMedicine	2013	9.9K
The Cancer Genome Atlas Pan-Cancer analysis project John N. Weinstein, Gordon B. Mills, Kenna Shaw, Nature Genetics	2013	9.1K
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma Tony Mok, Yi‐Long Wu, Sumitra Thongprasert, New England Journal of Medicine	2009	8.2K
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, New England Journal of Medicine	2012	7.9K
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer Naiyer A. Rizvi, Matthew D. Hellmann, Alexandra Snyder, Science	2015	7.8K
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial Roy S. Herbst, Paul Baas, Dong‐Wan Kim, The Lancet Pembrolizumab Versus DocetaxelOncologyClinical TrialsImmune Checkpoint InhibitorPharmacotherapy	2015	6.4K

Page 1